Trust Point Inc. Has $935,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Trust Point Inc. reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 36.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,068 shares of the company's stock after selling 1,760 shares during the period. Trust Point Inc.'s holdings in Medpace were worth $935,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. SBI Securities Co. Ltd. acquired a new position in shares of Medpace in the fourth quarter valued at $31,000. Jones Financial Companies Lllp boosted its position in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares during the period. Lindbrook Capital LLC boosted its position in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the period. Assetmark Inc. boosted its position in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares during the period. Finally, Colonial Trust Co SC boosted its position in shares of Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after acquiring an additional 105 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 20.30% of the company's stock.

Medpace Trading Down 1.9%

MEDP stock opened at $298.25 on Monday. The stock has a market capitalization of $8.57 billion, a P/E ratio of 23.61, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The firm has a 50-day moving average price of $298.85 and a 200-day moving average price of $322.54.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the business earned $3.20 earnings per share. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and reduced their target price for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Finally, Robert W. Baird cut their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.